Autopsy report · NCT04652258

Pyrexia Management Using an IL-6 Antibody in BRAF+ Melanoma Patients Treated with Dabrafenib/ Trametinib +/- Immunotherapy

“too few patients could be included”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 9 months before it stopped.
• 20 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

University of Zurich

Sponsor type

University, hospital or other

Conditions

Pyrexia

Interventions

Actemra

Participants

20

Sites

1

Countries

Switzerland

Trials that died the same way

• The Antidepressant Effect of Right Temporal Low Frequency rTMS Compared to Sham
  “Too few patients included” (97% match in meaning)
• Epidermal Cells Delivery and Acute Burns
  “Not enough patients included” (91% match in meaning)
• Ridge Preservation Comparing Simultaneous vs. Delayed Grafting
  “Not enough patients available” (85% match in meaning)
• Physical Activity Program and Nutrition Therapeutic Education During Treatment of Head and Neck Cancer Population
  “Not enough patients” (83% match in meaning)
• Duration of Postoperative Antibiotic Prophylaxis in Facial Fractures
  “Limited number of patients” (80% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.